Kidney patients on dialysis: new study checks blood thinner safety
NCT ID NCT04006093
First seen Apr 05, 2026 · Last updated May 12, 2026 · Updated 5 times
Summary
This study looked at how a single dose of the blood thinner apixaban is processed in the body of people with end-stage kidney disease who are on peritoneal dialysis, compared to people with normal kidney function. Researchers measured drug levels in the blood and urine over time. 24 adults took part. The goal was to understand dosing needs, not to treat a disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RENAL INSUFFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Caen
Caen, 14000, France
Conditions
Explore the condition pages connected to this study.